DEA, FDA Address Adderall Shortage by Urging Drugmakers to Boost Production
August 3, 2023Amid the ongoing shortage of prescription stimulants used to treat ADHD, the Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) issued a joint letter this week urging key stakeholders, including manufacturers, distributors, pharmacies, and payors, to work together to resolve drug shortages as quickly as possible.
The letter calls for the development of ADHD diagnostic criteria for adults, re-evaluation of drug quota allotments, adoption of non-stimulant and digital therapeutics where appropriate, and the thoughtful and responsible prescription of stimulant medications.Since the FDA first reported a shortage of Adderall (the brand name for the immediate-release formulation of amphetamine mixed salts used to treat ADHD) in October 2022, 38% of ADDitude readers say they have experienced problems accessing ADHD medication, according to a recent survey of 10,044 caregivers and adults.
Patient advocates and legislators have called on federal agencies to do more to combat the nationwide Adderall shortage since late last year.In December 2022, Rep.
Read more on additudemag.com
